Watching Shares Of GSK; UBS Note Says ACIP Working Group Recommends Universal RSV Vaccine for Age 75+ From SCD; No Endorsement for Ages 50-59 Due to Limited Data; 60-74 Recommendation Only for "At Risk"
Watching Shares Of GSK; UBS Note Says ACIP Working Group Recommends Universal RSV Vaccine for Age 75+ From SCD; No Endorsement for Ages 50-59 Due to Limited Data; 60-74 Recommendation Only for "At Risk"
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.